Antonia S, et al. Overall survival with durvalumab versus placebo after chemoradiotherapy in stage III NSCLC: updated results from PACIFIC. IASLC 2018, abstract PL02.01.
Optimaliseren van behandeling en follow-up bij plaveiselcelcarcinoom van de vulva
okt 2019 | Gynaecologische oncologie